Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
5 Health Care Stocks Cathie Wood Favors
04:07pm, Thursday, 09'th Jun 2022
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
5 Cathie Wood Stocks to Buy in June
11:00am, Thursday, 09'th Jun 2022
Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on Inves
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
02:08pm, Friday, 03'rd Jun 2022 Benzinga
Upgrades
Keefe, Bruyette & Woods upgraded the previous rating for Regions Financial Corp (NYSE:RF) from Underperform to Market Perform. For the first quarter, Regions Financial had an EPS of $0.55, c
Expert Ratings for Exact Sciences
01:08pm, Friday, 03'rd Jun 2022 Benzinga
Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
1
0
0
Last 3
Exact Sciences to participate in June investor conferences
06:00am, Friday, 27'th May 2022
MADISON, Wis. , May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following con
Why Is Exact Sciences (EXAS) Down 22.5% Since Last Earnings Report?
06:17pm, Thursday, 26'th May 2022 Zacks Investment Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exact Sciences (EXAS) Down 22.5% Since Last Earnings Report?
03:48pm, Thursday, 26'th May 2022
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences Won't Likely Escape Consolidation In The Industry
05:47am, Wednesday, 25'th May 2022
The current tight macro environment is conducive to consolidation in Biotech. Exact Sciences needs to turn cash flow positive to avoid liquidity problems.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
03:22pm, Monday, 23'rd May 2022 Zacks Investment Research
Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
12:48pm, Monday, 23'rd May 2022
Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations
12:00pm, Saturday, 21'st May 2022 The Motley Fool
Our roundtable found three biotechs with a nice cash cushion.
Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
07:34am, Saturday, 14'th May 2022
Exact Sciences continues to record strong growth and is expected to report growth for the foreseeable future. Regardless of the steady revenue growth, the EXAS stock is under a lot of selling pressure
Why Cathie Wood's Flagship ETF Slumped This Week
08:19pm, Thursday, 12'th May 2022 The Motley Fool
The highly prominent investor's ETFs are suffering in the tech sell-off.
Exact Sciences to participate in May investor conference
06:00am, Monday, 02'nd May 2022
MADISON, Wis. , May 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conf
2 Healthcare Stocks That Could Go Parabolic
03:07pm, Thursday, 28'th Apr 2022 The Motley Fool
These two companies are poised for a comeback.
